In contrast to TERT promoter mutations, TP53 alterations are not usually found in preneoplastic lesions [39] and their incidence increased progressively from early to advanced HCC (15.5% BCLC-0 vs. 35% BCLC-C) [32]. The gene discussed is TP53; the disease is hepatocellular carcinoma.